What is Erste Group Bank’s Estimate for NVO FY2026 Earnings?

Novo Nordisk A/S (NYSE:NVO) – Investment analysts at Erste Group Bank reduced their FY2026 EPS estimates for Novo Nordisk A/S in a research report issued to clients and investors on Monday, July 27th. Erste Group Bank analyst H. Engel now forecasts that the company will earn $3.20 per share for the year, down from their previous forecast of $3.22. The consensus estimate for Novo Nordisk A/S’s current full-year earnings is $3.39 per share.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Tuesday, March 31st. The company reported $1.03 EPS for the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%. The business had revenue of $10.85 billion for the quarter.

Other equities research analysts have also recently issued research reports about the company. HSBC reiterated a “hold” rating on shares of Novo Nordisk A/S in a report on Monday, July 6th. Wall Street Zen downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Saturday, June 20th. Zacks Research lowered Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a research note on Monday, July 13th. Nordea Equity Research upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Friday, June 19th. Finally, Citigroup reiterated a “neutral” rating on shares of Novo Nordisk A/S in a research report on Monday, July 20th. Five investment analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $65.56.

Novo Nordisk A/S Trading Down 0.1%

Shares of Novo Nordisk A/S stock opened at $51.55 on Friday. Novo Nordisk A/S has a 1 year low of $35.12 and a 1 year high of $64.16. The company has a debt-to-equity ratio of 0.59, a current ratio of 0.79 and a quick ratio of 0.56. The business has a 50 day moving average price of $46.87 and a 200 day moving average price of $45.49. The company has a market capitalization of $230.17 billion, a P/E ratio of 12.10, a P/E/G ratio of 4.70 and a beta of 0.77.

Institutional Investors Weigh In On Novo Nordisk A/S

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Platform Technology Partners grew its holdings in shares of Novo Nordisk A/S by 39.2% during the 2nd quarter. Platform Technology Partners now owns 10,941 shares of the company’s stock worth $525,000 after purchasing an additional 3,079 shares during the period. Fortis Group Advisors LLC raised its holdings in Novo Nordisk A/S by 145.5% in the second quarter. Fortis Group Advisors LLC now owns 72,916 shares of the company’s stock valued at $3,496,000 after buying an additional 43,213 shares during the period. Allen Wealth Management LLC purchased a new position in Novo Nordisk A/S in the second quarter valued at approximately $205,000. Pine Valley Investments Ltd Liability Co acquired a new position in Novo Nordisk A/S during the second quarter valued at approximately $2,324,000. Finally, Avidian Wealth Enterprises LLC lifted its position in Novo Nordisk A/S by 17.5% during the second quarter. Avidian Wealth Enterprises LLC now owns 31,634 shares of the company’s stock valued at $1,517,000 after buying an additional 4,708 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Expanded Wegovy access: Novo Nordisk partnered with Crux to offer simpler benefit designs and more predictable pricing for U.S. employer health plans. The agreement could reduce affordability barriers and broaden access to Wegovy, supporting future prescription growth. Novo Nordisk Teams Up With Crux To Expand Wegovy Access
• Positive Sentiment: Oral Wegovy opportunity: The European Commission’s approval of Novo’s once-daily oral Wegovy pill provides a new growth avenue in obesity treatment. Combined with the U.S. employer-access deal, the developments have encouraged optimism about wider GLP-1 adoption. Novo Nordisk Is Up After EU Wegovy Pill Approval And US Access Deal
• Positive Sentiment: Strong underlying product demand: Analysts expect Ozempic and Wegovy sales to be the primary focus of the upcoming second-quarter report, with oral launches and label expansions potentially supporting continued growth. Broader investor commentary also identifies Novo as a major beneficiary of the expanding GLP-1 market. How Will Ozempic and Wegovy Sales Aid NVO’s Upcoming Q2 Results?
• Neutral Sentiment: Results approaching: Investors are waiting for quarterly evidence that Ozempic and Wegovy sales can offset mounting competitive pressure. The earnings report may be a near-term catalyst, but expectations could also increase volatility if sales, pricing, or guidance disappoint. How Will Ozempic and Wegovy Sales Aid NVO’s Upcoming Q2 Results?
• Negative Sentiment: CagriSema litigation: A U.S. judge allowed parts of a shareholder lawsuit to proceed. Investors allege Novo misled them about a key CagriSema clinical trial, creating legal, reputational, and potential financial risks for the company’s next-generation obesity pipeline. Why Shareholders Are Suing Novo Nordisk Over CagriSema
• Negative Sentiment: Valuation and competition concerns: Commentary argues that much of Novo’s GLP-1 opportunity may already be reflected in the stock, while competitive pressure could limit upside and pricing power. Novo Nordisk: Too Late For A Great Opportunity

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.